ImmunTraCkeR® Results On Prediction of Response To Cancer Immunotherapy Selected For Presentation At ASCO Annual Meeting

ImmunID, the immune companion diagnostics for precision medicine company, today announces that a collaborative work on prediction of response to the anti-PD1 and anti-CTLA-4 immune checkpoint inhibitors in melanoma using ImmunTraCkeR® has been selected for a poster presentation during the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3-7, 2016. These results we generated in collaboration with Zurich University Hospital (Switzerland) and the NKI (The Netherlands), two leading European clinical centers in Immuno-Oncology.

“We are honored that the ASCO Scientific Program Committee has selected this collaborative work describing the use of the ImmunTraCkeR® assay for prediction of response to the immune checkpoint cancer immunotherapy,” said Dr Nicolas Pasqual, Co-Founder and Chief Scientific Officer of ImmunID. “We are looking forward to sharing updated ImmunTraCkeR® data in this prestigious scientific forum, and to discussing the data and our future development plans with key immuno-oncology scientific and clinical experts during the ASCO meeting” added Dr Bernhard Sixt, ImmunID’s Chairman and Chief Executive Officer.

With over 30,000 attendees, the ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO’s Annual Meeting represent the extent of progress made each year in the fight against cancer. To learn more about the ASCO Annual meeting: http://am.asco.org/